KALA (KALA) CFO discloses insider sales at $0.82–$0.84

Rhea-AI Filing Summary

KALA BIO (KALA) reported insider transactions by its Chief Financial Officer, Mary Reumuth. On 10/22/2025, she sold 32,230 shares of common stock at a weighted average price of $0.83, with individual trades ranging from $0.82 to $0.84. On 10/23/2025, she sold an additional 967 shares at $0.82.

Following these transactions, her reported beneficial ownership was 29,873 shares after the first sale and 28,906 shares after the second sale, held directly. A footnote states the 28,906 balance includes unvested RSUs.

Insights

Insider transactions analyst

Routine Form 4 sales; modest size at sub-$1 prices.

The CFO of KALA BIO disclosed two open-market sales: 32,230 shares at a weighted average of $0.83 on 10/22/2025 and 967 shares at $0.82 on 10/23/2025. The price range for the larger sale was $0.82–$0.84, and the filing notes availability of detailed breakdowns upon request.

Post-transaction beneficial ownership was 29,873 then 28,906 shares (direct), with a footnote indicating the 28,906 includes unvested RSUs. This reads as an administrative disclosure of insider activity.

Given the limited size and standard nature of these trades, the likely market impact is minimal. Actual effects, if any, depend on trading liquidity and investor interpretation of insider activity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reumuth Mary

(Last) (First) (Middle)

C/O KALA BIO, INC.

1167 MASSACHUSETTS AVENUE

(Street)

ARLINGTON MA 02476

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KALA BIO, Inc. [ KALA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
10/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/22/2025		S		32,230	D	$0.83(1)	29,873(2)	D
Common Stock	10/23/2025		S		967	D	$0.82	28,906(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

2. Includes 28,906 unvested RSUs.

	/s/ Mary Reumuth	10/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did KALA's CFO report?

She sold 32,230 shares at a weighted average of $0.83 on 10/22/2025 and 967 shares at $0.82 on 10/23/2025.

What price range applied to the larger KALA insider sale?

The 32,230-share sale occurred at prices ranging from $0.82 to $0.84, inclusive.

How many KALA shares does the CFO report owning after the sales?

Beneficial ownership was 29,873 shares after the first sale and 28,906 shares after the second, held directly.

Do the reported KALA holdings include RSUs?

Yes. A footnote states the 28,906-share figure includes unvested RSUs.

What is the role of the reporting person at KALA?

She is an Officer, serving as Chief Financial Officer.

Was the sale made under a Rule 10b5-1 plan?

The excerpt references the checkbox but does not indicate selection; no plan status is stated in the provided text.